Cannabis Science Global Consortium

Cannabis Science Global Consortium

The CBIS Global Consortium provides the us with a framework to cooperate and collaborate with...

 
  • The objective of the consortium is to harness the collective expertise of our global partners to investigate the use of Cannabinoids for the treatment of a variety of indications, including cancers, neurological conditions, pain management, the treatment of HIV and AIDS, and epilepsy.


    The Cannabis Science Global Consortium will link universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside. The CBIS Global Consortium will also enable the Company to more strategically coordinate its initiatives, including those focused on education, job creation, and skills training.


    There are three primary elements in Cannabis Science's drug development program:


    Defining the effectiveness and specificity of cannabinoids being tested;

    Identifying and testing drug delivery mechanisms; and

    Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in our randomized controlled trials. The Company's initial results point to the importance of drug delivery systems and the impact of co-interventions

  • Category
    General
  • Created
    Wednesday, 23 January 2019
  • Group admin
    Raymond C. Dabney

Become an iCannabinoid Ambassador

GET INV

Observational Studies

PART

Activity Stream

Osaruname Osayi-Osazuwa shared Raymond C. Dabney's status 1 week ago

Attending the GHC Summit is how I got involved with iCannabinoid. I had just finished my Masters thesis about prescription drug abuse and misuse and the rest is history.

Next month May 24-26 is the 2019 Harvard GHC Summit !!

Our team will be be attending for the 3rd year in a row and are very excited as every year it...
Show more

The Company is in the process of getting a third-party, independent valuation to establish the value of its CBN patent for the Canadian, U.S.,... Show more

Notifications

Events

Sorry, we currently have no events.
View All Events